StockNews.com Begins Coverage on Adaptimmune Therapeutics (NASDAQ:ADAP)

Analysts at StockNews.com assumed coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) in a research report issued to clients and investors on Friday. The firm set a "buy" rating on the biotechnology company's stock.

Separately, Mizuho lowered their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an "outperform" rating for the company in a report on Wednesday, November 27th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $2.18.

Adaptimmune Therapeutics Stock Performance

Shares of ADAP traded down $0.01 during trading hours on Friday, hitting $0.28. The company had a trading volume of 2,890,668 shares, compared to its average volume of 1,687,463. Adaptimmune Therapeutics has a 12 month low of $0.26 and a 12 month high of $1.65. The firm has a market cap of $70.83 million, a price-to-earnings ratio of -1.26 and a beta of 2.52. The business has a fifty day moving average of $0.54 and a 200-day moving average of $0.69. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62.

Remove Ads

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. Equities analysts anticipate that Adaptimmune Therapeutics will post -0.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Two Seas Capital LP acquired a new position in Adaptimmune Therapeutics in the fourth quarter valued at $7,992,000. Two Sigma Investments LP lifted its stake in Adaptimmune Therapeutics by 33.5% in the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock valued at $41,000 after buying an additional 19,146 shares during the period. Two Sigma Advisers LP grew its position in shares of Adaptimmune Therapeutics by 492.0% during the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock worth $38,000 after buying an additional 58,787 shares during the period. Jane Street Group LLC increased its stake in Adaptimmune Therapeutics by 87.7% in the fourth quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company's stock valued at $176,000 after purchasing an additional 152,780 shares in the last quarter. Finally, Long Focus Capital Management LLC grew its stake in shares of Adaptimmune Therapeutics by 54.1% in the 4th quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company's stock valued at $11,040,000 after buying an additional 7,194,503 shares during the period. Institutional investors own 31.37% of the company's stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.